Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Bekker, L., Moodie, Z, Grunenberg, N, Laher, F, Tomaras, G., Cohen, K., Allen, M, Malahleha, M, Mngadi, K, Daniels, B, Innes, C, Bentley, C, Frahm, N, Morris, D., Morris, L, Mkhize, N., Montefiori, D., Sarzotti-Kelsoe, M, Grant, S, Yu, C, Mehra, V., Pensiero, M., Phogat, S, DiazGranados, C., Barnett, S., Kanesa-Thasan, N, Koutsoukos, M, Michael, N., Robb, M., Kublin, J., Gilbert, P. B, Corey, L, Gray, G., & McElrath, M. The Lancet HIV, 5(7):e366-e378, 2019. PMCID: PMC6028742
bibtex   
@article{Bekkeretal2019,
  title={{Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in 
low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.}},
  author={Bekker, LG and Moodie, Z and Grunenberg, N and Laher, F and
 Tomaras, GD and Cohen, KW and 
Allen, M and Malahleha, M and Mngadi, K and Daniels, B and Innes, C and
 Bentley, C and Frahm, N and Morris, DE and 
Morris, L and Mkhize, NN and Montefiori, DC and Sarzotti-Kelsoe, M and
 Grant, S and Yu, C and 
Mehra, VL and Pensiero, MN and Phogat, S and DiazGranados, CA and
 Barnett, SW and Kanesa-Thasan, N and 
Koutsoukos, M and Michael, NL and Robb, ML and Kublin, JG and
 Gilbert, Peter B and Corey, L and Gray, GE and 
McElrath, MJ},
  journal={The Lancet HIV},
  volume={5},
  number={7},
  pages={e366-e378},
  year={2019},
  note={PMCID:
    PMC6028742}
}

Downloads: 0